DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Hemostasis And Tissue Sealing Agents Market Analysis By Product And Segment Forecasts To 2022" report to their offering.
The global hemostasis and tissue sealing agents market is expected to reach USD 7.4 billion by 2022.
The global hemostasis and tissue sealing agents market has gained popularity over time due to its ability in preventing blood loss. Rapid growth of minimal invasive technology and rising demand for faster recovery by patients is expected to promote market growth over the forecast period.
According to the CDC, approximately 150 million of American population is currently suffering with at least one chronic condition, which leads to surgeries and even mortality at times. An estimate over the rising incidence was made by the CDC, which concluded that over 48% of the entire American population is expected to suffer by chronic condition.
The demand for wound management is expected to rise with increasing chronic disease incidence over the next seven years. The Public Health Agency of Canada in its report stated that the chronic disease occurrence rate is anticipated to increase by 14% annually and four out of five cases are of high risk requiring immediate treatment and surgeries.
- Johnson & Johnson
- CryoLife Inc.
- Advance Medical Solution (AMS) Group Plc.
- Cohera Medical Inc.
- Integra Life Sciences Corporation
- Pfizer Inc.
- C R Bard Inc.
- Cohesion Technologies Inc
- HyperBranch Medical Technology
- Biomet Inc.
- Covidien Plc
- B Braun Medical Inc.
- Smith & Nephew
Key Topics Covered:
1. Methodology and Scope
2. Executive Summary
3. Hemostasis and tissue sealing agents Industry Outlook
4. Hemostasis and tissue sealing agents Product Outlook
5. Hemostasis and tissue sealing agents Regional Outlook
6. Competitive Landscape
For more information visit http://www.researchandmarkets.com/research/4fksqc/hemostasis_and